Dietary sodium restriction enhances the renoprotective efficacy of endothelin-A receptor antagonism in proteinuric chronic kidney disease
In brief
Low-salt diet let endothelin blockade reduce proteinuria by 300 micrograms per minute
In a 12-person crossover study, an endothelin-A blocker reduced proteinuria by about 300 micrograms per minute only during a 14-day low-sodium diet, not during participants' usual diet. Blood pressure and other systemic effects were similar with either diet; whether these short-term kidney changes lead to lasting protection remains unknown.
- Journal
- Kidney international (Q1)
- Published
- 19 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Dan Pugh, Gavin B Chapman, Victoria James, Alexandra Armstrong, Fiona A Chapman, Vanessa Melville, et al.
- PMID
- 43057618
- DOI
- 10.1016/j.kint.2026.10.033
Why clinicians should know about it
- Picked for Nephrology (top studies of the week, 22 November 2026): Randomized crossover study of sodium restriction and CKD pharmacotherapy
Abstract
INTRODUCTION: Endothelin-A receptor antagonists (ERAs) are emerging as an important treatment for proteinuric chronic kidney disease (CKD). As with renin-angiotensin-aldosterone system (RAAS) inhibition, dietary sodium intake may influence their therapeutic efficacy, but this has not been investigated. Here, we examined whether dietary sodium restriction enhances the systemic and kidney effects of acute selective endothelin-A (ETA) receptor antagonism in proteinuric CKD. METHODS: In a randomized, double-blind, placebo-controlled crossover study, 12 adults (mean age 46 years) with non-diabetic proteinuric CKD (mean eGFR 55 mL/min/1.73 m2; median proteinuria 1.8 g/day) receiving maximally tolerated RAAS inhibition completed two 14-day dietary interventions (habitual dietary sodium intake [13.3 g salt/day] and dietary sodium restriction [6.3 g salt/day, approximating guideline-recommended levels]) in random order. During each dietary period, participants underwent two study visits and received intravenous infusion of either placebo or the selective ET A receptor antagonist, BQ123. Systemic hemodynamics, arterial stiffness, kidney hemodynamics and proteinuria were assessed following each intervention. RESULTS: BQ123 produced comparable reductions in systolic blood pressure (about 12-14 mmHg), systemic vascular resistance and arterial stiffness under both dietary conditions and increased kidney blood flow (about 320-335 mL/min) irrespective of dietary sodium intake. In contrast, significant reductions in glomerular filtration rate (peak placebo-adjusted reduction: about 5 mL/min/1.73 m2), effective filtration fraction (peak reduction about 1.5%), and proteinuria (about 300 μg/min) were observed only during dietary sodium restriction and not during habitual sodium intake. CONCLUSIONS: Dietary sodium restriction enhances the short-term kidney efficacy of selective endothelin-A receptor antagonism in proteinuric CKD while preserving its beneficial systemic hemodynamic effects. As ERAs become established therapies for proteinuric kidney disease, these findings suggest that adherence to dietary sodium restriction may maximize their kidney-protective benefits. Whether the acute changes demonstrated here translate into long-term kidney protection requires prospective evaluation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.